Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
التنسيق:	Journal article
اللغة:	English
منشور في:	MDPI 2021

مواد مشابهة

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
حسب: Michael Riste, وآخرون
منشور في: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
حسب: Thomas, Z, وآخرون
منشور في: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
حسب: Tameris, M, وآخرون
منشور في: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
حسب: Tameris, M, وآخرون
منشور في: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
حسب: Mcshane, H
منشور في: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
حسب: Manjaly Thomas, Z, وآخرون
منشور في: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
حسب: Rowland, R, وآخرون
منشور في: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
حسب: Michele Tameris, وآخرون
منشور في: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
حسب: Harris, S, وآخرون
منشور في: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
حسب: Meyer, J, وآخرون
منشور في: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
حسب: Meyer, J, وآخرون
منشور في: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
حسب: Zita-Rose Manjaly Thomas, وآخرون
منشور في: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
حسب: Anne Wajja, وآخرون
منشور في: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
حسب: Wajja, A, وآخرون
منشور في: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
حسب: Sander, C, وآخرون
منشور في: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
حسب: Minassian, A, وآخرون
منشور في: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
حسب: Harris, S, وآخرون
منشور في: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
حسب: Odutola, A, وآخرون
منشور في: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
حسب: Odutola, A, وآخرون
منشور في: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
حسب: Dieye, T, وآخرون
منشور في: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
حسب: Wilkie, M, وآخرون
منشور في: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
حسب: Whelan, K, وآخرون
منشور في: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
حسب: Pathan, A, وآخرون
منشور في: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
حسب: Pathan, A, وآخرون
منشور في: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
حسب: Owiafe, P, وآخرون
منشور في: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
حسب: Tandakha N Dieye, وآخرون
منشور في: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
حسب: Kathryn T. Whelan, وآخرون
منشور في: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
حسب: Wilkie, M, وآخرون
منشور في: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
حسب: Tandakha N. Dieye, وآخرون
منشور في: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
حسب: Minhinnick, A, وآخرون
منشور في: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
حسب: C.N. Govind, وآخرون
منشور في: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
حسب: F. Ismail, وآخرون
منشور في: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
منشور في: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
حسب: Raksha Rimal, وآخرون
منشور في: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
حسب: Giovana Rodrigues Pereira, وآخرون
منشور في: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
حسب: Neeraj Raizada, وآخرون
منشور في: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
حسب: Mcshane, H, وآخرون
منشور في: (2016)

TB or not TB?
حسب: Andrew Pirotte, وآخرون
منشور في: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
حسب: Satti, I, وآخرون
منشور في: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
حسب: Satti, I, وآخرون
منشور في: (2014)